相关实验视频
Updated: Jul 9, 2026

12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
20.7K
在欧洲MYO7A患者队列中的多中心纵向前性研究:疾病过程和对基因疗法的影响
Francesco Testa1, Ester Carreño2, L Ingeborgh van den Born3
1Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.
Investigative ophthalmology & visual science
|June 17, 2024
概括
这项研究跟踪了53名患有MYO7A基因变异导致阿舍尔综合征的患者,揭示了疾病进展缓慢. 眼底自光模式是确定视网膜损伤阶段和为基因治疗选择患者的关键.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 是一个遗传学.
- 视网膜疾病 视网膜疾病
背景情况:
- 阿舍尔综合征是一种遗传性疾病,导致听力和视力丧失.
- MYO7A基因变异是阿舍氏综合征的常见原因.
- 了解与MYO7A相关的视网膜变的自然史对于患者管理至关重要.
研究的目的:
- 在患有MYO7A基因变异的患者中调查视网膜变的自然史.
- 分析视觉敏度,视野和视网膜结构随着时间的推移的进展.
- 评估底部自光模式在疾病分期中的作用.
主要方法:
- 对53名患有MYO7A变异的患者进行了前性纵向研究.
- 基线和两次年度后续访问.
- 评估最佳校正的视力敏度 (BCVA),视野,电网红图, fundus成像,微观测量,OCT和 fundus自光.
主要成果:
- 在两年内观察到疾病进展缓慢.
- 视力较好的眼睛的BCVA降低,视力较差的眼睛没有显著变化.
- 基线时的年龄与BCVA相关,视野和黄斑敏感性.
- 底部自光模式 (状斑块,中央低自光,环形模式) 与疾病严重程度有关.
结论:
- 这项研究证实了与MYO7A相关的视网膜发育不良症的慢性疾病进展.
- 底部自光模式作为视网膜损伤的客观生物标志物.
- 自体光模式可以帮助患者选择未来的基因疗法试验.
更多相关视频
相关概念视频
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

